<DOC>
	<DOC>NCT00988988</DOC>
	<brief_summary>Participants are asked to be in this study because they have multiple sclerosis, are currently treated with glatiramer acetate (GA, CopaxoneÂ®) injections and have redness, pain, swelling, itching or a lump at the injection site. The purpose of this study is to determine if the use of ethyl-a-guanida-methyl ethanoate (AGEE) will decrease histamine response measured by redness, swelling, and itch response following subcutaneous injection of glatiramer acetate (GA) for the treatment of Multiple Sclerosis (MS).</brief_summary>
	<brief_title>The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Able to give informed consent Between ages 1965 Laboratory supported diagnosis of multiple sclerosis Currently treated with injectable GA, experiencing wheal and flare after injection Unable to give informed consent Treated with any other therapy for Multiple Sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>AGEE</keyword>
	<keyword>histamine response</keyword>
</DOC>